InvestSMART

Conneqt Health Limited (ASX:CQT)

ALERT: Price-sensitive ASX Announcement for CQT
Current share price for CQT : $0.020 -0.015 (-42.86%)+
Announcement
Release
30 Oct 2025 9:46AM
Price at Release
$0.035
Full Release
download
Summary
Conneqt Health Limited reported significant growth and strategic advancements in their September 2025 Quarterly Activities Report. The company achieved a 50% quarter-on-quarter growth in Pulse sales and an annualized revenue run-rate exceeding US$3.5 million. They introduced a new pricing model for the Pulse device to expand market access while maintaining healthy margins. Conneqt Health also secured a Phase 2b clinical-trial contract in the US, valued at A$1.1 million, as they transitioned to a software-recurring revenue model for their SphygmoCor XCEL enterprise product. The company completed a corporate rebrand to unify consumer and clinical businesses and closed the quarter with A$2.7 million cash, alongside a new A$2 million Convertible Note Facility from C2 Ventures, subject to shareholder approval.
Key Points
  • Conneqt Health maintained strong growth in Pulse sales with a 50% quarter-on-quarter increase.
  • Pulse revenue reached an annualized run rate of US$3.5 million.
  • Introduced a new pricing model for Pulse, reducing the device price to US$249 and adding in-app report and Care+ membership purchases.
  • Secured a Phase 2b U.S. clinical-trial contract valued at A$1.1 million.
  • Transitioned to a consumption-based model for SphygmoCor XCEL, enhancing enterprise business scalability.
  • Completion of corporate rebrand from Cardiex Limited to Conneqt Health Limited.
  • Closing cash at the end of the quarter was A$2.7 million.
  • Convertible Note Facility of A$2 million secured from C2 Ventures, pending shareholder approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.